ClinicalTrials.gg

UCB S.A. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 581 studies whose lead sponsor is UCB S.A. or one of 23 companies grouped under it. 24 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 23 registry names, not the registry’s. See them and correct one ↓

Compare UCB with Johnson & Johnson and Bristol-Myers Squibb →

Pipeline: 16 programs

Each counted once: 16 with a study UCB S.A. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 4 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of UCB S.A.’s own registered studies; UCB S.A.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs UCB S.A.’s studies test, most open studies first — 46 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 46; every drug is on its own page, and each page lists its sponsors.

Coming up

14 of UCB S.A.’s studies under way reach primary completion within a year, 8 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 2D
  3. J’27
  4. F
  5. 3M
  6. A
  7. 3M
  8. 2J
  9. J
  10. A
  11. S
  12. 3O
  13. 1N

The 12 nearest

Show 7 more

Add all 14 to your calendar (.ics) → With an account.

All 581 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now244%Recruiting 20 · Enrolling by invitation 3 · Not yet recruiting 1
  • Under way, not recruiting132%
  • Completed47482%
  • Stopped early6311%Terminated 52 · Withdrawn 11
  • Status unknown or other71%No longer available 5 · Approved for marketing 1 · Available 1

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 3711
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 1026

By the year each study started; 160 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to UCB S.A..

  • UCB Pharma
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    242 studies →
  • UCB Biopharma SRL
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    130 studies →
  • UCB Biopharma S.P.R.L.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    48 studies →
  • UCB BIOSCIENCES, Inc.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    29 studies →
  • UCB Pharma SA
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    28 studies →
  • UCB BIOSCIENCES GmbH
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    21 studies →
  • Zogenix, Inc.
    Acquired — became part of UCB S.A., Mar 7, 2022 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    19 studies →
  • UCB Japan Co. Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    14 studies →
  • UCB Celltech
    Acquired — became part of UCB S.A., Jul 6, 2004 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Candid Therapeutics
    Acquired — became part of UCB S.A., Jun 17, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
    Acquired — became part of UCB S.A., Mar 7, 2022 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • UCB Pharma GmbH
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Ra Pharmaceuticals
    Acquired — became part of UCB S.A., Apr 2, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • UCB S.A. - Pharma Sector
    Division
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • UCB Korea Co., Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Zogenix MDS, Inc.
    Acquired — became part of UCB S.A., Mar 7, 2022 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Ra Pharmaceuticals, Inc.
    Acquired — became part of UCB S.A., Apr 2, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Neurona Therapeutics
    Acquired — became part of UCB S.A., Jun 2, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Engage Therapeutics, Inc.
    Acquired — became part of UCB S.A., 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • UCB Italy s.p.a.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Korea UCB Co., Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • UCB Pharma SA, Belgium
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • UCB PHARMA Inc. (US)
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions UCB S.A. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 581. Browse all 581 →